Finally, Chen et al. also constructed humanized bispecific IgG1 subclass antibodies against HER2 and PD-L1, which showed stronger ADCC activity and a better anti-tumor effect than monoclonal antibodies or combination therapy in the late stage of humanized HER2-positive tumor transplantation model [103]. This evidence concerns the gene CD274 and neoplasm.